Warren was appointed CEO of Bio-Me on 01 March 2022. Before that, he was the COO of the company since 2018.

Warren is a microbiologist with a key interest in the design and development of improved molecular techniques for microbiome analysis. He holds a PhD in microbiology and a MSc in immunology and immunogenetics from the University of Manchester.

After meeting Morten Isaksen, he left behind a successful UK life sciences career to come to Norway and build up a company with the focus of enabling rapid, high precision microbiome analysis for clinical applications. Warren is passionate about supporting microbiome therapeutics development and is chairman of the Pharmabiotics Research Institute OMICs task group.

Arne Materna, PhD

Co-CEO & Board Member

Arne joined Bio-Me as Chief Technology Officer of Bio-Me in September 2023, and was appointed Co-CEO on July 1^st 2024.  Arne brings a wealth of experience in the development and commercialization of leading-edge bioinformatics platforms and products with a particular focus on microbiology and next-generation sequencing. He joined Ares Genetics as Managing Director and CEO from CosmosID Inc., where he served as Vice President of Products. Before CosmosID, he held leadership positions and senior roles at QIAGEN, CLC Bio (acquired by QIAGEN in 2013) and Pacific Biosciences. He obtained his doctorate in life science at the University of Konstanz, Germany, and gained experience in microbial genetics and microbiome research as a post-doctoral fellow at the Massachusetts Institute of Technology (MIT), prior to joining the industry in 2010. Arne is also a member of Bio-Me’s Board of Director

Jon Alm Eriksen, PhD

Head of Software & Data Science

Jon is a physicist with an affection for mathematical modeling, programming, and computation. He received his PhD in physics from the University of Oslo in 2015. Following a postdoc in biostatistics at the Norwegian Centre for Mental Disorders Research (NORMENT), he transitioned to the industry where he has held several roles dedicated to developing machine learning models and other data-driven applications in Arundo Analytics and more recently in Novelda.

Runar Vige, MSc MBA

Chief Business Officer

Runar holds an MSc in physical activity and health/exercise physiology from the Norwegian School of Sports Sciences and earned an MBA from BI Norwegian Business School. He brings ~20 years of experience from the life science industry in companies such as Pfizer, Pronova BioPharma, and BASF.

Runar has an extensive product development background, including clinical development of pharmaceuticals and Medical Food products, as well as claims substantiation of nutritional ingredients. More lately as a business developer and commercial manager, developing and managing partnerships for distribution of Medical Food products in Europe and the US.

Anne-Grethe Reichelt, PhD

Head of Sales & Marketing

Anne-Grethe earned her PhD in Molecular Biology from the University of Bergen and has an MSc from the University of Tromsø. She brings over 10+ years of Sales and Business Development experience from the Life Science industry and has broad customer and product knowledge, a high customer focus, and is solution-oriented.

Anne-Grethe has been working with Bio-Me from the beginning through her previous position at Thermo Fisher Scientific and is now thrilled to be part of the team. She also holds a position as President-elect at ICF Norway. Anne-Grethe is a strong advocate for thinking outside of the box and working with the microbiome in several areas.

Satyasree Kuraganti, MSc

Lab Management

Satya earned a master’s degree in biotechnology from Osmania University in Hyderabad, India, and a bachelor’s degree in microbiology from Kakatiya University, Adilabad, India.

Satya has excellent knowledge of biotechnological laboratory equipment, and experience in cell biology, bioinformation, immunology, molecular biology, and microbiology, with a special focus on genetics, RNA/DNA technologies, and bioprocess-technologies.

Maria Valente Oksvold, BSc

Office Manager

Maria graduated from the University of Oslo with a BSc in Bioscience in 2023, with a focus on microbiology and cell biology. She brings over many years of experience in business administration, management, and content creation thanks to supervising a successful coastal hotel in Tanzania and later being the manager at a prominent café in Oslo.

More recently, Maria worked in the communication and social media department at the Faculty of Science and Mathematics while finishing her bachelor’s degree.

Carl Christian Gilhuus-Moe, PhD

Chairman of the Board

Carl Christian was the founding President and CEO of Dynal Biotech AS, now part of Thermo Fisher Scientific Inc. Carl Christian is a Senior Advisor of NeoMed Management, a European-based venture capital fund focused on international healthcare and medical technology and Chairman of Sonitor Technologies AS and board member of Respinor AS. Carl Christian trained at the Swedish Institute of Management, the Sloan School of Management at the Massachusetts Institute of Technology and earned a PhD in clinical biochemistry from the University of Oslo.

Hilde Furberg, MSc

Board member

Broad senior leadership experience with over 35 years in Pharma/Biotech was lateste the Senior Vice President and Head of Rare Diseases EU in Sanofi Genzyme. Served as a non-executive director of Combigen, BerGenBio, Probi, Pronova, Clavis, Algeta and chair of the board for Blueprint Genetics. She is currently a board member of Calliditas, PCI Biotech, OncoZenge, Herantis, and Sedana Medical.

Sverre Munck, PhD

Board member

Sverre is a seasoned internet executive with 20 years of experience as EVP at Schibsted Media Group. Responsibilities include being Group CFO, managing Schibsted’s free newspapers under the 20minutes brand, starting up online classified sites such as compraventa.com and leboncoin.fr.

Since 2011, he has also been responsible for group strategy. He has substantial experience in strategy and business development, inter-nationalization/scaling and management coaching.

Morten is the founder of Bio-Me. He handed over the CEO role to Warren Flood in March 2022.
Morten has a PhD in Biotechnology and has been involved in many biotech start-ups, including Active Biotech, Affitech, and Genetic Analysis, to name a few.
During the last decade, Morten’s passion is to optimize gut microbiome analysis while contributing to understanding the challenges and solutions for optimizing microbiome-based Precision Medicine. Morten is also a member of Bio-Me’s Board of Directors.

Arne Materna, PhD

Co-CEO & Board Member

Arne joined Bio-Me as Chief Technology Officer of Bio-Me in September 2023, and was appointed Co-CEO on July 1^st 2024.  Arne brings a wealth of experience in the development and commercialization of leading-edge bioinformatics platforms and products with a particular focus on microbiology and next-generation sequencing. He joined Ares Genetics as Managing Director and CEO from CosmosID Inc., where he served as Vice President of Products. Before CosmosID, he held leadership positions and senior roles at QIAGEN, CLC Bio (acquired by QIAGEN in 2013) and Pacific Biosciences. He obtained his doctorate in life science at the University of Konstanz, Germany, and gained experience in microbial genetics and microbiome research as a post-doctoral fellow at the Massachusetts Institute of Technology (MIT), prior to joining the industry in 2010. Arne is also a member of Bio-Me’s Board of Director

Anne Marie Duus, BSc

Board member

Experienced executive with focus on business development in health products and concepts with commercial background. Board member, investor and advisor in health tech startups. Served as CEO of Skodsborg Health Center and business developer in Skandia and AP pension funds.

As an international executive, Dr. Heiner Dreismann brings more than 35 years of experience from biotech and healthcare companies, with a proven track record in general management with P&L responsibilities and management of corporate functions such as R&D, manufacturing, marketing, and business development. During his 25+ years in Roche’s diagnostic division, he also managed licensing and M&A opportunities. He is the former President and CEO of Roche Molecular Systems, a world leader in Molecular Diagnostics. Heiner has served on the boards of several public and private companies. He holds a PhD in Microbiology/Molecular Biology from Westphalian Wilhelms University, Münster.

Dr. Charles Stabell has a long track record in academia and as an entrepreneur, and is now an active high-tech investor and advisor. He was one of the co-founders and the CEO of GeoKnowledge, a firm that developed the de facto global standard tools for stochastic prospect assessment modeling of exploration opportunities in the petroleum industry. The company was acquired by Schlumberger in 2012. Charles was for 25 years in teaching and research, most recently as a professor in business strategy at the Norwegian School of Management (BI); earlier amongst other as an assistant professor in computers and information systems at the Graduate School of Business, Stanford University. Charles is an electronics engineer from ENSERG (Grenoble, France), has an MBA from McGill University (Montreal), and a PhD from the Sloan School of Management, Massachusetts Institute of Technology (MIT).

Morten is the founder of Bio-Me. He handed over the CEO role to Warren Flood in March 2022.
Morten has a PhD in Biotechnology and has been involved in many biotech start-ups, including Active Biotech, Affitech, and Genetic Analysis, to name a few.
During the last decade, Morten’s passion is to optimize gut microbiome analysis while contributing to understanding the challenges and solutions for optimizing microbiome-based Precision Medicine. Morten is also a member of Bio-Me’s Board of Directors.